poisar

Stocks · News reference

HC Wainwright Adjusts Price Target on Actuate Therapeutics to $10 From $15, Keeps Buy Rating

Fiscal.ai

HC Wainwright & Co. has revised its price target for Actuate Therapeutics, Inc. from $15 to $10 while maintaining a 'Buy' rating on the stock.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — ACTUATE THERAPEUTICS, INC. (ACTU)

    Filed: 2026-10-30 AccNo: 0001683168-26-008193 Size: 207 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing